文献速递头痛与眩晕

加卡奈珠单抗治疗慢性偏头痛:随机双盲安慰剂对照REGAIN研究

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
PubMed 文献 · Neurology · 2018-11-16

REGAIN是一项3期随机双盲安慰剂对照研究,纳入慢性偏头痛患者,按2:1:1随机接受安慰剂、加卡奈珠单抗120 mg(负荷240 mg)或240 mg每月皮下注射。主要终点为3个月双盲期内每月偏头痛头痛天数(MHD)较基线的总体平均变化,两个剂量组均优于安慰剂(p<0.001)。

要点

  • 加卡奈珠单抗120 mg和240 mg组每月MHD降低幅度均大于安慰剂,差异有统计学意义(p<0.001)。
  • 除240 mg组注射部位反应、红斑、瘙痒及鼻窦炎发生率高于安慰剂外,安全性与耐受性无临床意义差异。
  • 该干预性研究提供I级证据表明加卡奈珠单抗在减少每月MHD方面优于安慰剂。

核心结论

  • 加卡奈珠单抗两个剂量组在减少每月MHD方面均优于安慰剂,用于慢性偏头痛预防治疗似乎有效、安全且耐受良好。

研究设计与样本

  • 3期随机双盲安慰剂对照研究(REGAIN),含3个月双盲治疗期和9个月开放标签扩展期。
  • 纳入18至65岁慢性偏头痛患者,按2:1:1随机分为安慰剂组(n=558)、加卡奈珠单抗120 mg组(负荷240 mg,n=278)和加卡奈珠单抗240 mg组(n=277),每月皮下注射。

主要发现

  • 总样本基线每月MHD平均为19.4天。
  • 3个月双盲期内每月MHD总体平均降低:安慰剂组-2.7天,加卡奈珠单抗120 mg组-4.8天,加卡奈珠单抗240 mg组-4.6天(各剂量组与安慰剂比较p<0.001)。
  • 加卡奈珠单抗240 mg组相对于安慰剂,治疗中出现注射部位反应(p<0.01)、注射部位红斑(p<0.001)、注射部位瘙痒(p<0.01)和鼻窦炎(p<0.05)的发生率更高。
  • 除上述事件外,加卡奈珠单抗各剂量组与安慰剂在任何安全性或耐受性结局上均无临床意义差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. METHODS: A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migraine (Evaluation of Galcanezumab in the Prevention of Chronic Migraine [REGAIN]) was a phase 3 study with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Eligible patients 18 to 65 years of age with chronic migraine were randomized 2:1:1 to monthly subcutaneous injections of placebo (n = 558), galcanezumab 120 mg (with a 240-mg loading dose, n = 278), or galcanezumab 240 mg (n = 277). The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days (MHDs) during the 3-month double-blind treatment phase. RESULTS: Mean number of monthly MHDs at baseline was 19.4 for the total sample. Both galcanezumab dose groups demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo (placebo -2.7, galcanezumab 120 mg -4.8, galcanezumab 240 mg -4.6) (p < 0.001 for each dose compared to placebo). There were no clinically meaningful differences between galcanezumab doses and placebo on any safety or tolerability outcome except for a higher incidence of treatment-emergent injection-site reaction (p < 0.01), injection-site erythema (p < 0.001), injection-site pruritus (p < 0.01), and sinusitis (p < 0.05) in the galcanezumab 240-mg group relative to placebo. CONCLUSIONS: Both doses of galcanezumab were superior to placebo in reducing the number of monthly MHDs. Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine. CLINICALTRIALSGOV IDENTIFIER: NCT02614261. CLASSIFICATION OF EVIDENCE: This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018. PMID: 30446596. doi:10.1212/WNL.0000000000006640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。